SynthesisPharmacoEconomics2026

Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs.

Josep Darbà et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.